These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 239250)

  • 1. Cardiac adenylate cyclase activity in relation to beta-adrenergic responses.
    Wollemann M; Borbola J; Papp J; Szekeres L
    J Mol Cell Cardiol; 1975 Jul; 7(7):523-33. PubMed ID: 239250
    [No Abstract]   [Full Text] [Related]  

  • 2. [Hydroxybenzylpindolol--activation mechanism of adenylate cyclase and beta-adrenergic receptor].
    Yamamura H
    Nihon Rinsho; 1976; 34(3):534-9. PubMed ID: 6811
    [No Abstract]   [Full Text] [Related]  

  • 3. Catecholamine-sensitive adenylate cyclase of human fat cell ghosts: a comparative study using different beta-adrenergic agents.
    Kather H; Simon B
    Metabolism; 1977 Nov; 26(11):1179-84. PubMed ID: 20550
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiostimulatory effects of prenalterol, a beta-1 adrenoceptor partial agonist, in vivo and in vitro. Correlation between physiological effects and adenylate cyclase activity.
    Hedberg A; Carlsson E; Fellenius E; Lundgren B
    Naunyn Schmiedebergs Arch Pharmacol; 1982 Feb; 318(3):185-91. PubMed ID: 6121296
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activation of cardiac EP3 receptors by PGE1 reduces beta-adrenergic inotropic effects.
    Hohlfeld T; Schrör K
    Adv Exp Med Biol; 1997; 433():447-50. PubMed ID: 9561192
    [No Abstract]   [Full Text] [Related]  

  • 6. In kitten ventricular myocardium, the inotropic potency of an agonist is determined by both its intrinsic activity for the adenylyl cyclase and its affinity for the beta-adrenoceptors.
    Kaumann AJ
    Naunyn Schmiedebergs Arch Pharmacol; 1981 Aug; 317(1):13-8. PubMed ID: 6116196
    [No Abstract]   [Full Text] [Related]  

  • 7. Prenalterol, a non-selective beta-adrenoceptor ligand with absolute beta1-selective partial agonist activity.
    Hedberg A; Mattsson H; Carlsson E
    J Pharm Pharmacol; 1980 Sep; 32(9):660-1. PubMed ID: 6107374
    [No Abstract]   [Full Text] [Related]  

  • 8. Pharmacological analysis of the cardiac actions of xamoterol, a beta adrenoceptor antagonist with partial agonistic activity, in guinea pig heart: evidence for involvement of adenylate cyclase system in its cardiac stimulant actions.
    Hattori Y; Sakuma I; Nakao Y; Kanno M
    J Pharmacol Exp Ther; 1987 Sep; 242(3):1077-85. PubMed ID: 2888870
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of xamoterol on inotropic and lusitropic properties of the human myocardium and on adenylate cyclase activity.
    Böhm M; Mittmann C; Schwinger RH; Erdmann E
    Am Heart J; 1990 Dec; 120(6 Pt 1):1381-92. PubMed ID: 1978979
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structure-binding-activity analysis of beta-adrenergic amines--I. Binding to the beta receptor and activation of adenylate cyclase.
    Bilezikian JP; Dornfeld AM; Gammon DE
    Biochem Pharmacol; 1978 May; 27(10):1445-54. PubMed ID: 29638
    [No Abstract]   [Full Text] [Related]  

  • 11. Heterogeneity of adenylate cyclase-coupled beta-adrenergic receptors.
    Lefkowitz RJ
    Biochem Pharmacol; 1975 Mar; 24(5):583-90. PubMed ID: 235928
    [No Abstract]   [Full Text] [Related]  

  • 12. Cholinergic antagonism of beta-adrenergic stimulated action potentials and adenylate cyclase activity in rabbit ventricular cardiomyocytes.
    Watson JM; Vogel SM; Cotterell DJ; Dubocovich ML
    Eur J Pharmacol; 1988 Oct; 155(1-2):101-8. PubMed ID: 2468508
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Editorial: Selectivity in beta-adrenergic responses: clinical implications.
    Lefkowitz RJ
    Circulation; 1974 May; 49(5):783-6. PubMed ID: 4151328
    [No Abstract]   [Full Text] [Related]  

  • 14. Exfoliation of the beta-adrenergic receptor and the regulatory components of adenylate cyclase by cultured rat glioma C6 cells.
    Kassis S; Lauter CJ; Stojanov M; Salem N
    Biochim Biophys Acta; 1986 May; 886(3):474-82. PubMed ID: 2871868
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Cardiac beta receptors--experimental aspects].
    Kaumann AJ
    Z Kardiol; 1983 Feb; 72(2):63-82. PubMed ID: 6133398
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The resolution of dopamine and beta 1- and beta 2-adrenergic-sensitive adenylate cyclase activities in homogenates of cat cerebellum, hippocampus and cerebral cortex.
    Dolphin A; Hamont M; Bockaert J
    Brain Res; 1979 Dec; 179(2):305-17. PubMed ID: 41616
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Beta adrenergic receptors mediate adenylate cyclase responses in rat cerebral capillaries.
    Palmer GC
    Neuropharmacology; 1980 Jan; 19(1):17-23. PubMed ID: 6102354
    [No Abstract]   [Full Text] [Related]  

  • 18. Intrinsic sympathomimetic activity of (-)-pindolol mediated through a (-)-propranolol-resistant site of the beta1-adrenoceptor in human atrium and recombinant receptors.
    Joseph SS; Lynham JA; Molenaar P; Grace AA; Colledge WH; Kaumann AJ
    Naunyn Schmiedebergs Arch Pharmacol; 2003 Dec; 368(6):496-503. PubMed ID: 14608456
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Apparent superiority of H2-receptor stimulation and simultaneous beta-blockade over conventional treatment with beta-sympathomimetic drugs in post-acute myocardial infarction: cardiac effects of impromidine--a new specific H2-receptor agonist-in the surviving catecholamine-insensitive myocardium.
    Baumann G; Felix SB; Heidecke CD; Riess G; Loher U; Ludwig L; Blömer H
    Agents Actions; 1984 Oct; 15(3-4):216-28. PubMed ID: 6151806
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regulation of cardiac adenylate cyclase activity in rodent models of obesity.
    Strassheim D; Houslay MD; Milligan G
    Biochem J; 1992 Apr; 283 ( Pt 1)(Pt 1):203-8. PubMed ID: 1348926
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.